Taxanes in the treatment of breast cancer

A prodigy comes of age

Kathy Miller, George W. Sledge

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The taxanes, paclitaxel and docetaxel, are among the most promising new agents in the treatment of breast cancer. Responses are routinely seen in >30% of patients with metastatic disease, including those who have previously received anthracyclines. Combination therapy has increased response rates but as yet has not improved the overall survival of patients with metastatic disease. Improved survival with the addition of paclitaxel to standard adjuvant therapy reported in a recently completed trial suggests the true impact of the taxanes has not yet been realized.

Original languageEnglish
Pages (from-to)121-136
Number of pages16
JournalCancer Investigation
Volume17
Issue number2
StatePublished - 1999

Fingerprint

Taxoids
docetaxel
Breast Neoplasms
Paclitaxel
Survival
Anthracyclines
Therapeutics
Prodigy

Keywords

  • Breast cancer
  • Chemotherapy
  • Docetaxel
  • Paclitaxel

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Taxanes in the treatment of breast cancer : A prodigy comes of age. / Miller, Kathy; Sledge, George W.

In: Cancer Investigation, Vol. 17, No. 2, 1999, p. 121-136.

Research output: Contribution to journalArticle

Miller, Kathy ; Sledge, George W. / Taxanes in the treatment of breast cancer : A prodigy comes of age. In: Cancer Investigation. 1999 ; Vol. 17, No. 2. pp. 121-136.
@article{57a8c9d0c3204b90837630770a33c9b3,
title = "Taxanes in the treatment of breast cancer: A prodigy comes of age",
abstract = "The taxanes, paclitaxel and docetaxel, are among the most promising new agents in the treatment of breast cancer. Responses are routinely seen in >30{\%} of patients with metastatic disease, including those who have previously received anthracyclines. Combination therapy has increased response rates but as yet has not improved the overall survival of patients with metastatic disease. Improved survival with the addition of paclitaxel to standard adjuvant therapy reported in a recently completed trial suggests the true impact of the taxanes has not yet been realized.",
keywords = "Breast cancer, Chemotherapy, Docetaxel, Paclitaxel",
author = "Kathy Miller and Sledge, {George W.}",
year = "1999",
language = "English",
volume = "17",
pages = "121--136",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Taxanes in the treatment of breast cancer

T2 - A prodigy comes of age

AU - Miller, Kathy

AU - Sledge, George W.

PY - 1999

Y1 - 1999

N2 - The taxanes, paclitaxel and docetaxel, are among the most promising new agents in the treatment of breast cancer. Responses are routinely seen in >30% of patients with metastatic disease, including those who have previously received anthracyclines. Combination therapy has increased response rates but as yet has not improved the overall survival of patients with metastatic disease. Improved survival with the addition of paclitaxel to standard adjuvant therapy reported in a recently completed trial suggests the true impact of the taxanes has not yet been realized.

AB - The taxanes, paclitaxel and docetaxel, are among the most promising new agents in the treatment of breast cancer. Responses are routinely seen in >30% of patients with metastatic disease, including those who have previously received anthracyclines. Combination therapy has increased response rates but as yet has not improved the overall survival of patients with metastatic disease. Improved survival with the addition of paclitaxel to standard adjuvant therapy reported in a recently completed trial suggests the true impact of the taxanes has not yet been realized.

KW - Breast cancer

KW - Chemotherapy

KW - Docetaxel

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=0032968717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032968717&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 121

EP - 136

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 2

ER -